Shots:
- Bio-Thera and Dr. Reddy’s have entered into an exclusive commercialization and license agreement for BAT2506, a biosimilar version of Simponi (golimumab) & BAT2206, a biosimilar version of Stelara (ustekinumab)
- As per the agreement, Bio-Thera will handle the development, manufacturing, and supply of BAT2206 & BAT2506, while Dr. Reddy’s will manage regulatory approvals & commercialization in Southeast Asia (Cambodia, Indonesia, Malaysia, Philippines, Thailand, and Vietnam) and hold exclusive commercial rights for BAT2206 in Colombia
- BAT2506 & BAT2206 is a mAb targeting TNF-alpha & blocks IL-12 and IL-23 by preventing p40 from binding to the IL-12Rβ1 receptor on immune cells, respectively
Ref: Bio-Thera | Image: Bio-Thera and Dr. Reddy’s | Press Release
Related News:- Bio-Thera Collaborates with Intas Pharmaceuticals for the Commercialization of BAT2506 (Biosimilar, Simponi) Across the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
